



## Anti-human TIE-2

20140701BB



**FOR RESEARCH ONLY! NOT FOR HUMAN USE!**

<b>Cat.-no.:</b>	<b>102-PA111</b>
Size:	200 µg
Lot. No.:	According to product label
Country of origin:	Germany

**Preparation:** Produced from sera of rabbits pre-immunized with highly pure (>95%) recombinant human soluble TIE-2 (Thr19-Lys745) produced in insect cells.

### Target Background

<b>Synonyms:</b>	Endothelial tyrosine kinase, Tyrosine kinase with Ig and EGF homology domains-2
------------------	---

TIE-1 (tyrosine kinase with Ig and EGF homology domains 1) and TIE-2/TEK comprise a receptor tyrosine kinase (RTK) subfamily with unique structural characteristics: two immunoglobulin-like domains flanking three epidermal growth factor (EGF)-like domains and followed by three fibronectin type III-like repeats in the extracellular region and a split tyrosine kinase domain in the cytoplasmic region.

These receptors are expressed primarily on endothelial and hematopoietic progenitor cells and play critical roles in angiogenesis, vasculogenesis and hematopoiesis. Human TIE-2 cDNA encodes a 1124 amino acid (aa) residue precursor protein with an 18 residue putative signal peptide, a 727 residue extracellular domain and a 354 residue cytoplasmic domain. Two ligands, angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2), which bind TIE-2 with high affinity have been identified. Ang2 has been reported to act as an antagonist for Ang1. Mice engineered to overexpress Ang2 or to lack Ang1 or TIE-2 display similar angiogenic defects.

### References

1. Partanen J and DJ Dumont (1999) Curr Top Microbiol Immunol 237:159.
2. Takakura N et al, (1998) Immunity 9:677.
3. Procopio W et al, (1999) J Biol Chem 274:30196.

### Database References Antigen

<b>Protein RefSeq:</b>	NP_000450.2
<b>Uniprot ID:</b>	Q02763
<b>mRNA RefSeq:</b>	NM_000459.3

### Product Specifications

<b>Species reactivity</b>	human
<b>Clone/Ab feature</b>	Rabbit IgG
<b>Cross reactivity</b>	Mouse
<b>Host</b>	rabbit
<b>Clonality</b>	polyclonal
<b>Purification</b>	Protein A purified
<b>Immunogen</b>	Recombinant human sTIE-2 (RT Cat# S01-044)
<b>Formulation</b>	lyophilized
<b>Buffer</b>	PBS

**Stability:** The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C.

**Reconstitution:** Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.



**AVOID REPEATED FREEZE AND THAW CYCLES!**

### Applications


<b>Western Blot:</b>	Use at 2-5 µg/ml
<b>FACS:</b>	Use at 1-5 µg/ml

**NOTE: OPTIMAL DILUTIONS SHOULD BE DETERMINED BY EACH LABORATORY FOR EACH APPLICATION!**




## Anti-human TIE-2


### Handling/Applications



**Figure 1.** Western analysis of recombinant human and mouse sTIE-1 and sTIE-2 using a polyclonal antibody directed against human recombinant sTIE-2. There is a strong cross reactivity with mouse sTIE-2 but not with human and mouse sTIE-1 visible.



**Figure 2.** FACS analysis with primary human umbilical vein endothelial cells (HUVEC).



**Figure 3.** FACS analysis with primary human dermal lymphatic endothelial cells (HDLEC).